Drugs / IMC-003
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07118085 Comparator | Aug 2025 → May 2027 expected | — | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07593027 Comparator | Apr 2026 → Oct 2027 expected | pulmonary arterial hypertension | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07118085 ↗ |